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Invasive mucormycosis of the esophagus (rare) and gastrointestinal tract is emerging as an
important cause of concern in children. It usually affects immunosuppressed individuals.
However, infection of immunocompetent children is also seen. The diagnosis of mucor-
mycosis is difficult both at the clinical and the laboratory level, hence leading to unsatis-
factory treatment and high mortality rates. The infection is usually life threatening so an
early diagnosis and prompt administration of antifungal therapy is imperative.Mucormycosis refers to fungal infection seen in immuno-
suppressed individuals caused by a ubiquitous saprophytic
mold growing in soil and organic matter which produce hy-
phae after inhalation or ingestion. They belong to the order
mucorales.WhileMucor ismostly seen in immunosuppressed;
some fungi of the genus mucorales (Apophysomyces elegans
and Saksenaea vasiformis) are seen infecting immunocompe-
tent ones. The prevalence and incidence of opportunistic
mycoses have increased owing to several factors, including
longer survival of immunosuppressed individuals and ad-
vances in laboratory-based diagnosis of these diseases.
Mucormycosis is the third most frequent mold infection in
immunocompromised patients after candida and aspergillus [1]
andmay disseminate to rhinocerebral, pulmonary, cutaneous
and gastrointestinal (GI) areas. Unfortunately, diagnosis ofology, Maulana Azad Med
(J.B. Bhattacharya).
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s/by-nc-nd/4.0/).mucormycosis in both the clinical and the laboratory levels
remains difficult, leading to unsatisfactory treatment and
high mortality rates. Early diagnosis, surgical debridement,
systemic antifungal therapy, and control of underlying con-
ditions are the key elements in the successful management of
this infection. Most common predisposing factors are
malnutrition, prematurity, HIV, diabetes mellitus, leukaemia
and induced immunosuppression.Case report
A 1 year old boy was presented to the Pediatric Out-Patient
Department with complaints of dysphagia (more to solids
than liquids) and a recent history of difficulty in breathing forical College, B-126, Second floor, Sector-50, Noida, Uttar Pradesh
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birth weight of 3.5 kg, was born in a remote hospital. The child
had not undergone invasive procedures of any kind or been
hospitalized before for any disease. The mother gave history
of a single episode of diarrheawhen the child was amonth old
andwas given some local medication. Since then, he had been
experiencing the same symptoms on and off for which he took
treatment at various centers. The child was weaned at 6
months of age; however, proper weaning practices could not
be performed due to poor socio-economic status. At the age of
11 months the child developed inspiratory stridor due to
tracheal compression with regurgitation of feeds.
On examination the patient was sick-looking, conscious,
and afebrile with drooling of saliva. His weight was 9 kg (25th
percentile) and height was 75 cm (85th percentile). The pulse
rate was 120 beats/min and the respiratory rate was
40 breaths/min with chest retraction. The oxygen saturation
was 86% under 100% oxygen inhalation. Laboratory in-
vestigations showed hemoglobin 16 g/dl, total leukocyte count
12,000/mm3 with polymorphs 60%, lymphocytes 25%, eosin-
ophils 8%, and monocytes 7%. Platelet count was 2.8 lakhs/
mm3 and erythrocyte sedimentation rate was 20 mm/h. The
peripheral smear showed normal red blood cell picture (mean
corpuscular volume (MCV) e 98 fl, mean corpuscular hemo-
globin (MCH) e 27 pg and mean corpuscular hemoglobin
concentration (MCHC) e 32 g/dl. Tests for HIV and hepatitis C
virus serology were non-reactive. Upper GI contrast study
showed mild persistent luminal narrowing in cervical and
thoracic esophagus while the distal esophagus was normal.
[Fig. 1] Contrast enhanced computed tomography (CT) Neck
and Thorax showed asymmetrical diffuse wall thickening/
mass in the submucosal location involving cervical and
thoracic vertebrae (C4-T12) leading to esophageal narrowing.
Maximum esophageal wall thickness was 1.7 cm. There was
anterior displacement and compression of trachea. Based on
radiological findings diffuse leiomyomatosis or inflammatory
lesion or lymphoma was impressed.Fig. 1 e Upper gastrointestinal contrast study showing
persistent luminal narrowing in cervical and thoracic
esophagus.At the time of admission, the child was treated with anti-
biotics, and then injectable steroids added due to worsening
respiratory distress. Upper GI endoscopywas planned after CT
scan but due to the patient's deteriorating condition and dif-
ficulty in performing endoscopic procedure in severely stric-
tured esophagus an urgent resection of cervical and thoracic
esophagus with tracheostomy and feeding gastrostomy was
performed.
On histopathological examination the specimen was
received as a part of esophagus 9 cm long with a luminal
diameter of 2 cm. The entire wall was thickened up to 1 cm
without a well-defined growth.
Multiple sections were taken and the esophageal wall
demonstrated granulomatous inflammation composed of
histiocytes, lymphocytes and many eosinophils along with
many giant cells some of which contained broad, aseptate and
branching hyphae [Fig. 2 high power view]. These hyphae also
presented in the subepithelium surrounded by granulomas.
These fungal hyphae were positive for periodic-acid Schiff
and silver stains. Stain for acid fast bacillus was negative. The
above pictures suggested mucormycosis.Discussion
Mucormycosis is a rare infection seen mostly in immuno-
compromised individuals causing a granulomatous inflam-
mation attributed to the prolonged course of infection. Known
for its vascular invasion, it is one of the leading causes for
invasive infection causing high morbidity and mortality. In a
large review of 929 patients with zygomycosis [2], diabetes
was the most common underlying risk factor (36%), followed
by malignancy (17%), solid organ transplantation (7%), des-
ferroxamine therapy (6%), and bone marrow transplantation
(5%). Most of these conditions are associated with impairment
immune function. Hematological malignancy associated
mucormycosis has been seen as an emerging problem. In a
study done by Pagano et al., 59 cases of the leukemic patients,
the majority of whom were neutropenic, developed mucormy-
cosis with a mortality of 80% [1]. Premature neonates having
an immature immune systemare known to be associatedwithFig. 2 e Microscopy showing a granulomatous inflammation
composed of chiefly many eosinophils along with broad,
aseptate, branching hyphae (high power view).
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period with intravenous antibiotics and steroids which alter
the already compromised gut flora leading to easy suscepti-
bility to mucorales [3]. In a study done by Agarwal et al. they
noticed that three neonates who had no radiological findings
of NEC were diagnosed to have GI mucormycosis [4]. Risk of
contracting mucormycosis increases with instrumentation of
any kind (oro-gastric instrumentation, endotracheal intuba-
tion) leading to mucosal injury. Our patient had none of the
above risk factors; however, improper weaning was specu-
lated to play some role.
Clinical and radiological pictures of mucormycosis often
mimic aspergillosis, but the antifungal treatments are
different. Culture is the definitive mode to identify the species
since many sub species other than Mucor (such as pathogenic
Rhizopus, Absidia, Morteirella and Cunninghamella and Basidio-
bolus) have also been seen to infect children. In tissue sec-
tions, all of these species appear the same, so culture is
imperative. When affected, stomach, colon, small intestine is
seen in decreasing frequency, however, esophageal involve-
ment although seen, is rare. In a review study done byMooney
andWagner, 34 children presented between ages 2 days and 15
years and the most common affected being <1 year of age. Of
34, 26 involved the GI tract, of which 18 were gastric, 14 were
large bowel, 10 as small bowel and 5 in esophagus [5].
Because GI mucormycosis is almost uniformly fatal in
both adults and children, diagnosis is usually made at au-
topsy and is frequentlymissed during life. A clinical diagnosis
of the condition has never been made [6]. An early diagnosis
in such cases either by an endoscopy-guided biopsy or sur-
gery plays an important role to administer therapy early.
Aggressive treatment in the form of IV amphotericin followed
by surgery is the mainstay of the treatment. Adequate
resection to reduce the fungal load and further complications
is vital; however, surgical resection depends on the general
condition, platelet count and neutrophil count. Survival of
the patient depends on the immunity of the patient and
virulence of the infecting organism. The commonly used
antifungals such as fluconazole are not effective in removing
mucorales, and hence the symptoms persist or even worsen.
First-line antifungal agents suggested by European Confer-
ence on Infections in Leukemia are liposomal amphotericin B
(L-AMB) and amphotericin-B lipid complex (ABLC). AMB is
challenged by its potentially severe side effects. L-AMB is
more effective, as it attains good concentration in the brain as
well as in the reticuloendothelial system. Posaconazole and
combinations of L-AMB/ABLC with caspofungin have been
suggested as second-line treatment. Even though pos-
aconazole exhibits good efficacy and has been used suc-
cessfully in few cases, it is not reliable as a first-line therapy,
as it has unpredictable bioavailability in patients with GI
involvement [7]. The prognosis of mucormycosis is grave
with neonatal mortality being 40% and in patients with he-
matological malignancies, it is 65e90% [7] owing commonlyto misdiagnosis and wrong treatment with extensive surgery
in an already compromised child. Until date, only seven
children of GI mucormycosis have been survived [3]. Our
patient received antifungal therapy (AMB and posaconazole)
and responded during the hospital stay; however, esophageal
reconstruction could not be performed due to against advice
discharge and loss of follow-up.Conclusion
Esophagealmucormycosis is a rare presentation in children. It
is difficult to diagnose as the clinical presentation may point
towards a more common different diagnosis. Hence, a high
suspicion in dysphagic patient with non-corrosive, non-
congenital, and non-peptic esophageal narrowing is crucial. A
thorough investigation with early surgery/biopsy for histo-
pathological diagnosis aided by microbiological or molecular
methods and aggressive antifungal treatment is mandatory in
both immunocompromised and immunocompetent in-
dividuals to reduce morbidity and mortality.Financial support and sponsorship
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